MAM
STRO icon

Meeder Asset Management’s Sutro Biopharma STRO Stock Holding History

Meeder Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-282
Closed -$9.76K – 1016
2024
Q3 		$9.76K Hold
282
– – ﹤0.01% 623
2024
Q2 		$8.27K Buy
+282
New +$11.2K ﹤0.01% 691
2021
Q4 		– Sell
-361
Closed -$68K – 2198
2021
Q3 		$68K Buy
361
+60
+20% +$11.4K ﹤0.01% 1007
2021
Q2 		$56K Buy
301
+139
+86% +$27.2K ﹤0.01% 1081
2021
Q1 		$37K Buy
+162
New +$38.4K ﹤0.01% 1198
2020
Q4 		– Sell
-466
Closed -$47K – 2198
2020
Q3 		$47K Buy
466
+208
+81% +$19.7K ﹤0.01% 970
2020
Q2 		$19K Buy
258
+34
+15% +$3.26K ﹤0.01% 1146
2020
Q1 		$23K Buy
224
+195
+672% +$20.5K ﹤0.01% 1193
2019
Q4 		$3K Hold
29
– – ﹤0.01% 1943
2019
Q3 		$3K Buy
+29
New +$2.93K ﹤0.01% 1894

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Meeder Asset Management's STRO Position: Q4 2024 in Review

Meeder Asset Management sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 282 shares — an estimated $9.76K sold.

Meeder Asset Management first reported a position in STRO in Q3 2019 and held it in 10 quarters. The position peaked at $68K in Q3 2021. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Meeder Asset Management reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 282 Sutro Biopharma shares in Q4 2024, an estimated $9.76K.
  • Meeder Asset Management first reported a position in Sutro Biopharma in Q3 2019 and held it in 10 quarters.
  • Meeder Asset Management's Sutro Biopharma position peaked at $68K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.